Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) and remains a major global public health concern. As per Mira Hleyhe et al. (2024), approximately 50 million individuals were chronically infected globally, with 0.2 million deaths in 2022. According to the Hepatitis C epidemiology forecast by Expert Market Research, prevalence trends continue to shape global disease burden.
Base Year
Historical Period
Forecast Period

Read more about this report - Request a Free Sample
Expert Market Research's “Hepatitis C Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of hepatitis C. It projects the future incidence and prevalence rates of hepatitis C cases across various populations. The study covers age, gender, and type as major determinants of the hepatitis C population. The report highlights patterns in the prevalence of hepatitis C over time and projects future trends based on multiple variables.
The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of hepatitis C in the 8 major markets.
Regions Covered
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV), primarily transmitted through exposure to infected blood. The infection can be acute or progress to chronic hepatitis C when the virus persists in the body. Chronic infection may cause progressive liver inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma if left untreated. Transmission commonly occurs through unsafe injections, sharing contaminated needles, and inadequately screened blood products. The disease is classified into different HCV genotypes, with genotypes 1–6 being the major groups, although their distribution varies geographically.
|
Parameter |
Insight |
|
Largest Patient Pool |
United States |
|
Fastest Growing Region |
India |
|
High-Risk Population |
People who inject drugs, individuals exposed to unsafe medical procedures, and populations with higher HCV prevalence |
|
Key Diagnostic Method |
HCV antibody testing followed by HCV RNA testing for confirmation of active infection |
|
Major Risk Factor |
Exposure to HCV-contaminated blood, particularly through injection drug use and unsafe injections |
|
Major gap in the market |
Underdiagnosis and limited linkage to confirmatory testing and curative treatment |
The hepatitis C epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the hepatitis C epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hepatitis C and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
|
Epidemiology Segment |
Key Insights |
|
Diagnosed Prevalent Cases of the Disease |
According to Mira Hleyhe et al., 2024, approximately 50 million people were chronically infected with hepatitis C globally, with 0.2 million deaths in 2022. The estimated global prevalence was approximately 1%, while India was estimated at around 1%. |
|
Gender-Specific Cases of the Disease |
As per the European Centre for Disease Prevention and Control, 2023, hepatitis C was reported more frequently among men than women in the EU/EEA, with a male-to-female ratio of 1.7:1, indicating a higher reported burden among males. |
|
Age-Specific Cases of the Disease |
According to the Centers for Disease Control and Prevention, 2023, persons aged 30–39 years had the highest reported rates of acute hepatitis C in the United States. In Japan, approximately 50% of patients were over 75 years old. |
|
Ethnicity-Wise Cases of the Disease |
According to the Centers for Disease Control and Prevention, 2023, the reported acute hepatitis C rate among non-Hispanic American Indian/Alaska Native persons was 2.3 times that of non-Hispanic White persons, representing the highest rate among reported racial and ethnic groups. |
|
Mortality and Survival Analysis of the Disease |
According to Mira Hleyhe et al., 2024, hepatitis C was associated with approximately 0.2 million deaths globally in 2022. In the United States, the Centers for Disease Control and Prevention, 2023 reported 11,194 hepatitis C-related deaths during 2023. |
|
Disease Type |
Prevalence |
|
Genotype 1 |
Genotype 1 is the most common HCV genotype worldwide and in the United States, with common subtypes including 1a and 1b. |
|
Genotype 2 |
Genotype 2 is found globally, with common subtypes including 2a, 2b, and 2c. |
|
Genotype 3 |
Genotype 3 is the second most common HCV genotype globally and is highly prevalent in South Asia; genotype 3a is a common subtype. |
|
Others |
Other HCV genotypes have more geographically concentrated distributions, including genotypes 4, 5, 6, 7, and 8. |

Read more about this report - Request a Free Sample
The hepatitis C epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.
|
Country |
Key Insights |
|
United States |
According to the Centers for Disease Control and Prevention, 2023, 4,966 new acute hepatitis C cases and 101,525 newly reported chronic hepatitis C cases were recorded. The estimated number of acute HCV infections was 69,000, and the acute hepatitis C rate was 1.5 cases per 100,000 population. Persons aged 30–39 years had the highest rates. The American Liver Foundation reports that approximately 2.7 million people in the United States have chronic hepatitis C infection. |
|
Germany |
The epidemiological burden of hepatitis C in Germany can be considered within the broader European context. According to the European Centre for Disease Prevention and Control, 2023, hepatitis C surveillance across 29 EU/EEA countries recorded 28,622 cases, corresponding to a crude rate of 7.4 cases per 100,000 population. |
|
France |
Hepatitis C epidemiology in France forms part of the broader EU/EEA surveillance landscape. As per the European Centre for Disease Prevention and Control, 2023, reported hepatitis C cases across 29 EU/EEA countries showed a male-to-female ratio of 1.7:1, with 35–44 years representing the most affected age group. |
|
Italy |
Italy contributes to the broader European hepatitis C epidemiological burden. According to the European Centre for Disease Prevention and Control, 2023, there were 28,622 hepatitis C cases reported across 29 EU/EEA countries, with 4.9% classified as acute and 34.1% as chronic. |
|
Spain |
The epidemiological profile of hepatitis C in Spain can be considered within the EU/EEA surveillance context. According to the European Centre for Disease Prevention and Control, 2023, hepatitis C was more frequently reported among men, with a male-to-female ratio of 1.7:1 across the monitored EU/EEA population. |
|
United Kingdom |
Hepatitis C epidemiology in the United Kingdom is considered within the European regional context provided. According to Mira Hleyhe et al., 2024, approximately 50 million people globally were living with chronic HCV infection, while the global prevalence of hepatitis C was approximately 1%. |
|
Japan |
According to Yuri Komaki et al., 2022, approximately 50% of patients with hepatitis C virus infection in Japan were over 75 years old, highlighting a substantial concentration of the identified patient population among older adults. |
|
India |
As per R. Ingle et al., 2023, the prevalence of hepatitis C infection in India was estimated at approximately 1%. The study reported an overall seroprevalence of 1.8%, while the cited World Health Organization estimate placed India's prevalence at around 1%. |
A major epidemiological gap in hepatitis C remains the identification of undiagnosed infections and timely linkage to curative treatment across the United States, European countries, Japan, and India. Expanded screening among populations with previous blood exposure, people who inject drugs, and other higher-risk groups can improve case detection. Integration of HCV antibody and reflex RNA testing into routine healthcare pathways may reduce diagnostic delays. Emerging opportunities include decentralized testing, simplified treatment pathways, and improved surveillance systems. Strengthening screening-to-treatment programs can support progress toward hepatitis C elimination by identifying infections earlier and increasing access to effective antiviral therapy.
Hepatitis C is now considered a curable viral infection in most patients with appropriate treatment. The primary treatment approach is oral direct-acting antiviral (DAA) therapy, which targets specific proteins required for HCV replication. Common regimens include combinations containing sofosbuvir, velpatasvir, glecaprevir, or pibrentasvir, with treatment selection based on clinical factors and previous treatment history. Therapy generally lasts 8–12 weeks and can achieve high sustained virologic response rates. Effective antiviral therapy reduces the risk of cirrhosis, liver failure, and hepatocellular carcinoma associated with chronic HCV infection.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Report Features |
Details |
|
Base Year |
2025 |
|
Historical Period |
2019-2025 |
|
Forecast Period |
2026-2035 |
|
Epidemiology Statistics Provided |
|
|
Segmentation Provided |
|
|
Geographies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.